Clinical Trials Browser

Resectable Non-Small Cell Lung Cancer

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05022394 2022-05-27

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03770299 2022-03-24

CheckMate 9TN

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04758949 2022-01-11

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

Phase 1/2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

NCT03417037 2018-04-30

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03023904 2018-04-25

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03048136 2018-04-17

CheckMate 955

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02924233 2017-08-28

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02639234 2017-07-31

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02950038 2017-02-13

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Neo-Kan

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

CheckMate 79X

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

CheckMate 9TN

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

CheckMate 955

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)